Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02134964 · ClinicalTrials.gov registry record · Phase 1
Phase 1 Safety and PK Study of OLT1177 Capsules
A Phase 1 study, sponsored by Olatec Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 35
- Enrollment target
NCT02134964 is a Phase 1 study that has completed, run by Olatec Therapeutics. The registered enrollment target is 35 participants.
The verdict
NCT02134964, a Phase 1 study, has completed, sponsored by Olatec Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 35 participants
- Enrollment target
Study Summary
This study is a randomized, placebo-controlled, sequential ascending-dose study of healthy volunteers after administration of single or multiple dose(s) of investigational drug (OLT1177 Caps or Placebo Caps). A total of 36 subjects will be enrolled across 6 cohorts, and subjects in each cohort will be randomized in a ratio of 5 active to 1 placebo.
Interventions
- DRUG Placebo Capsules
- DRUG OLT1177 Capsules
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2014-06 |
| Est. Completion | 2014-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02134964
The ClinicalTrials.gov registry entry for NCT02134964 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Olatec Therapeutics, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo Capsules is the first listed.
NCT02134964 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02134964 about?
NCT02134964 is a clinical study titled "Phase 1 Safety and PK Study of OLT1177 Capsules". This study is a randomized, placebo-controlled, sequential ascending-dose study of healthy volunteers after administration of single or multiple dose(s) of investigational drug (OLT1177 Caps or Placebo Caps). A total of 36 subjects will be enrolled across 6 cohorts, and subjects in each cohort will ...
What is the current status of trial NCT02134964?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 35 participants. The study started on 2014-06. Estimated completion is 2014-12.
What interventions are being tested in trial NCT02134964?
The interventions under investigation include: Placebo Capsules (DRUG), OLT1177 Capsules (DRUG).
Who is sponsoring clinical trial NCT02134964?
This trial is sponsored by Olatec Therapeutics, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.